Search clinical trials for: AZD5462

Total 113 results

AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Healthy Participants

United States
AstraZeneca
Parexel

Completed

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Completed

A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (CIRRUS)

Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) | Laymen Terminology Chronic Bronchitis and Emphysema

Bulgaria, Germany, Hungary, Ukraine
AstraZeneca

Not yet recruiting

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA)

Chronic Heart Failure
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Healthy Volunteer | Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca

Terminated

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Lymphoma | Multiple Myeloma | Advanced Solid Tumors | Hematologic Malignancies

United States
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
AstraZeneca

Completed

Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

Asthma

Germany
AstraZeneca

Completed

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability (OAK)

Safety and Tolerability, | Advanced Solid Malignancy, | Pharmacokinetics, Pharmacodynamics, | Tumour Response,

United Kingdom, Netherlands
AstraZeneca
Quintiles, Inc.

Completed

This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca

Completed

AZD5438 in Patients With Advanced Solid Malignancies

Neoplasms

United States
AstraZeneca

Completed

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (NIMBUS)

Asthma

Bulgaria, Czech Republic, Mexico, Poland, Russian Federation, South Africa, United Kingdom, Germany, Romania, Ukraine, Canada, Hungary, Slovakia
AstraZeneca

Completed

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis (STRATUS)

Bronchiectasis | Lung Disease | Respiratory Diseases

Czech Republic, United Kingdom, Poland
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers

Healthy

United Kingdom
AstraZeneca

Completed

Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069

Healthy

United Kingdom
AstraZeneca

Completed

Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069 (JSMAD)

Healthy

United Kingdom
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
Oxford University Hospitals NHS Trust
University of Oxford; Cancer Research UK; National Institute for Health Research...

Completed

Phase 1 Trial of CXD101 in Patients With Advanced Cancer

Advanced Cancer

United Kingdom
AstraZeneca

Completed

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

Healthy

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

Antiplatelet Effect
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Unknown

A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)

Adenocarcinoma of the Prostate

United Kingdom
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. (PYRUS)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.

United Kingdom, United States
AstraZeneca
Parexel

Completed

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Prostate Cancer

Spain, United States
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
University of Nottingham
AstraZeneca; Cancer Research UK; National Cancer Research Network

Completed

AKT Inhibitor in Oestrogen Positive Breast Cancer (STAKT)

Invasive Breast Cancer

United Kingdom
AstraZeneca

Terminated

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Spain, United States, Korea, Republic of, France, Portugal, Australia, Italy
AstraZeneca

Completed

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Bioavailability and AUC

United Kingdom
AstraZeneca

Completed

An Open-Label, Dose-Escalation Study of AZD2461

Refractory Solid Tumors | Cancer Tumor

United States
University of Michigan Rogel Cancer Center

Terminated

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
AstraZeneca

Completed

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor

United Kingdom, United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...

Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma | Recurrent Meningioma | NF2 Gene Mutation

United States
University of Rome Tor Vergata

Completed

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

COVID-19 Pandemic | Transplant-Related Disorder

Italy
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects

Healthy

United Kingdom
AstraZeneca

Completed

AZD5423 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects

Healthy

Japan
AstraZeneca

Completed

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Asthma

United Kingdom
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

Primary Sclerosing Cholangitis

United States, United Kingdom, Israel, Germany, Canada
AstraZeneca
Parexel

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

Healthy Subjects (Indication: Asthma)

United Kingdom
AstraZeneca

Completed

A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Healthy | Asthma

United Kingdom
AstraZeneca
Quotient Sciences

Completed

A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

Healthy Volunteer

United Kingdom

Search clinical trials for: AZD5462

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations